Lupin joins hands with Alvion to commercialize Cardiometabolic medicines in Southeast Asia
Mumbai: Global pharma major, Lupin Limited, announced today that the company has entered into a licensing agreement with Alvion Pharmaceuticals P.C. to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.
Commenting on the announcement, Gabriel Georgy, Regional Head Southeast Asia, Lupin said "Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. We look forward to expanding our partnership with Alvion over the coming years."
By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at email@example.com Contact no. 011-43720751